|Bid||84.00 x 900|
|Ask||85.40 x 2200|
|Day's range||83.77 - 85.32|
|52-week range||77.04 - 98.52|
|Beta (5Y monthly)||0.55|
|PE ratio (TTM)||21.49|
|Forward dividend & yield||3.20 (3.84%)|
|Ex-dividend date||04 Mar 2021|
|1y target est||104.80|
NVS earnings call for the period ending September 30, 2021.
Novartis (NVS) reports mixed results in the third quarter, as key brands maintain momentum but generics business remains weak.
Novartis AG may spin off or sell its Sandoz generic-drug unit after it consistently failed to meet expectations, with U.S. sales plummeting this year amid the Covid-19 pandemic. Chief Executive Officer Vas Narasimhan says now is the right moment to reconsider its strategic fit, and the company will explore all options. He also discusses third-quarter growth and Covid treatments with Bloomberg's Dani Burger on "Bloomberg Markets: Europe."